Contract facts
FederalNo full NAICS 325412 intel page yet. Browse NAICS intelligence
LEUKINE 250MCG/VIL INJ is a federal award for Aspr/Orm-Sns held by Partner Therapeutics, Inc. Estimated value $59M ($59M obligated). Current period of performance ends Mar 29, 2024. Last award drew 1 bidder. Place of performance: BOSTON, MA.
Recompete timing
PublicCurrent PoP ended Mar 29, 2024 (875 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Incumbent footprint
Public recordPartner Therapeutics, Inc — $147.4M obligated across 9 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 75A50322F80018?
75A50322F80018 (Leukine 250mcg VIL INJ) is a Aspr/Orm-Sns award with an estimated value of $59M, currently held by Partner Therapeutics, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 75A50322F80018?
Aspr/Orm-Sns awarded 75A50322F80018 to Partner Therapeutics, Inc.
Who is the incumbent on 75A50322F80018?
Partner Therapeutics, Inc is the incumbent with $147.4M across 9 related awards in SCOUT’s public footprint. The current period of performance ends Mar 29, 2024.
When does Partner Therapeutics, Inc’s 75A50322F80018 come up for recompete?
SCOUT tracks a period-of-performance end of Mar 29, 2024. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.